Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 182, Issue 3, 2000, Pages 751-757

  Equils, Ozlem ^a   Garratty, Eileen ^b   Wei, Lian S ^b   Plaeger, Susan ^b   Tapia, Millie ^b   Deville, Jaime ^b   Krogstad, Paul ^b   Sim, Myung Shin ^b   Nielsen, Karin ^b   Bryson, Yvonne J ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CELL DIFFERENTIATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFANT; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; VIRUS INHIBITION; VIRUS ISOLATION;

ADOLESCENT; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CHILD; COCULTURE TECHNIQUES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPHENOTYPING; INFANT; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MALE; NELFINAVIR; PROSPECTIVE STUDIES; RECEPTORS, CCR5; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; STAVUDINE; VIRAL LOAD; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0033827618     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315758     Document Type: Article

References (40)

1. Combination therapy with zidovudine, didanosine and saquinavir
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate
4. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection
5. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors
6. + cell counts despite persistently detectable HIV load
7. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
8. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
9. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
10. CXCR4 expression during lymphopoiesis: Implications for human immunodeficiency virus type 1 infection of the thymus
11. Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants
12. CD8 naive T cell counts decrease progressively in HIV-infected adults
13. T cell activation in pediatric AIDS pathogenesis: Three-color immunophenotyping
14. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
15. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
16. Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype
17. Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children
18. Replication and tropism of human immunodeficiency virus type 1 as predictors of disease outcome in infants with vertically acquired infection
19. Immunological and virological markers of disease progression in HIV-infected children
20. In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression
21. HIV biological phenotype: Prognosis marker for transmission, disease progression and therapy
22. Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS
23. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals
24. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency
25. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent
26. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
27. + cell depletion in human immunodeficiency virus type 1-infected SCID-hu mice suggest direct viral killing of thymocytes in vivo
28. Differential tropism and replication kinetics of human immunodeficiency virus type 1 isolates in thymocytes: Coreceptor expression allows viral entry, but productive infection of distinct subsets is determined at the postentry level
29. Differential tropism of HIV-1 isolates for distinct thymocyte subsets in vitro
30. Human lymphocyte differentiation in primary and secondary immunodeficiency diseases
31. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection
32. HIV phenotype switching during antiretroviral therapy: Emergence of saquinavir-resistant strains with less cytopathogenicity
33. Dual effect of interleukin 4 on HIV-1 expression: Implications for viral phenotypic switch and disease progression
34. Virologic and immunologic markers of disease progression in pediatric HIV infection
35. Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4(+) T-helper 1 (Th1)- and Th2-type conditions
36. + T-lymphocyte regeneration after intensive chemotherapy
37. Changes in thymic function with age and during the treatment of HIV infection
38. Sustained CD4 T cell response after virologic failure of protease inhibitor regimens: Correlation between CD4 and viral load response after two years of therapy